FIELD: medicine.
SUBSTANCE: group of inventions relates to immunology, and can be used to produce a vaccine against the influenza virus. Influenza virus vaccine for administration by spraying into the nasal mucosa contains: (i) an inactivated whole virion of influenza and (ii) a basic gel substance comprising a carboxyvinyl polymer which is treated by applying an external shear force to enhance spraying performance. Vaccine is characterised by absence of adjuvant content. Group of inventions also relates to the use of a vaccine to prevent influenza by spraying into the nasal mucosa.
EFFECT: use of this group of inventions makes it possible to obtain a combination of a gel base for spraying into the nasal mucosa comprising a carboxyvinyl polymer which is treated by adding an external shear force to impart spray properties, and inactivated whole influenza virus, allowing to enhance immune induction in humans without an adjuvant.
10 cl, 2 ex, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| NASAL VACCINE COMPOSITION AGAINST HEPATITIS B AND ITS PRODUCTION METHOD | 2018 |
|
RU2773357C2 |
| RHINOVACCINATION SYSTEM FOR INFLUENZA VACCINE | 2015 |
|
RU2696483C2 |
| MUCOSAL INFLUENZA VIRUS VACCINE AND METHOD FOR INFLUENZA PREVENTION | 2004 |
|
RU2390351C2 |
| SECRETORY IgA AND IgG ANTIBODY INDUCER | 2006 |
|
RU2440138C2 |
| COMPUTER-OPTIMIZED ANTIGENS WITH WIDE REACTIVITY SPECTRUM FOR INFLUENZA VIRUSES OF H5N1 AND H1N1 | 2013 |
|
RU2639551C2 |
| VACCINE COMPOSITION FOR NON-IMMUNISED INDIVIDUALS | 2013 |
|
RU2661407C2 |
| MEDICINAL ANTIGEN CARRIER ENABLING TRANSMUCOSAL AND TRANSDERMAL ADMINISTRATION, METHOD OF MUCOSAL IMMUNITY INDUCTION, MUCOSAL VACCINE AND RELATED DRUG DELIVERY SYSTEM | 2005 |
|
RU2396090C2 |
| MUCOSAL VACCINE | 2011 |
|
RU2570394C2 |
| VACCINE COMPOSITION | 2013 |
|
RU2655627C2 |
| HEPATITIS B VACCINE TRANSNASAL SYSTEM | 2019 |
|
RU2795235C2 |
